Nabriva Therapeutics plc, of Dublin, acquired Zavante Therapeutics Inc., of San Diego, for up-front consideration of about 8.2 million of Nabriva's ordinary shares (which includes an indemnity holdback) to Zavante's former stockholders upon completion of the acquisition.